VALN
$11.01
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Recent News
Is It Time To Reassess Valneva (ENXTPA:VLA) After Its Strong Recent Share Price Rally
If you are wondering whether Valneva is priced attractively right now, it helps to step back and look at what the recent share performance and valuation metrics are really telling you. The stock last closed at €5.08, with returns of 9.6% over 7 days, 23.7% over 30 days, 34.0% year to date and 39.2% over 1 year, compared with declines of 7.3% over 3 years and 52.2% over 5 years. These mixed return figures sit against a backdrop of ongoing interest in Valneva’s vaccine portfolio and...
Valneva’s Lyme disease vaccine offers beacon of hope amid 2025 sales dip
Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline candidates.
Valneva to withdraw Chikungunya vaccine from US amid safety woes
The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Wednesday afternoon with the NYSE Health Care Index dropping 0.5% a
Valneva trims R&D footprint by shutting French facility
The consolidation comes a week after the vaccine specialist downgraded its 2025 guidance.